|
|
|
| home > epc > spring 2003 > the changing face of diagnostics and its impact on the pharmaceutical industry - an update |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
The diagnostic sector, at least as defined for the in vitro diagnostics (IVD) business, is little brother to the pharma industry. The markets are globally distributed in a very similar fashion but the 2002 IVD market was only valued at just over 20 billion dollars (US$24.1 billion) with global growth of less than five per cent per annum (4.3%). This is in great contrast to the pharma market valued at almost 400 billion (US$395 billion) and achieving growth of above 10 per cent per annum (12 per cent). The global distributions are compared in Figure 1 .
Three years ago in this publication the possible impact of diagnostics on the pharma industry was examined, a strong driving force at that time being the reduced growth of the IVD market. The need to identify new areas for growth in diagnostics was linked to the belief that tests that could define those patients most likely to respond to specific drugs or classes of drugs as therapeutics: theranostics.
The pharma industry has, over several decades, resisted the use of diagnostic testing for the selection of therapeutics. The potential for loss of drug sales through better selection of drugs of choice or even the non-selection of particular therapeutics was not considered economically sound. The major change over the last three years has been in the technological developments that have created at least "the start of the beginning" of personalised medicine.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
3rd African Regulatory Conference (ARC)
3-4 May 2012, Accra, Ghana
The African Regulatory Conference offers the opportunity for key stakeholders active on the continent, including representatives from Ministry of Health, local and multinational pharmaceutical companies, to meet to exchange views, discuss topics of interest and identify focus areas for ongoing efforts to increase patient access to new and improved medicines.
More info >> |
|
 |
News and Press Releases |
 |
Kallik’s new approach to asset management delivers long term artwork automisation
Marketing and compliance departments can now have greater control over their assets –from logos and images to labelling copy – and a roadmap to automated artwork generation, thanks to Kallik’s online Asset Repository. It is the most cost-effective way to lay the foundation for future automisation of the artwork and labelling generation. The practice of centralising the content in a web-based asset library and reusing those assets across all marketing and trade communications is saving businesses thousands, if not millions, of pounds.
More info >> |
|
|
